Present and future therapeutic strategies for melioidosis and glanders

Area of Science:

• Microbiology and Infectious Diseases
• Bacteriology
• Drug Discovery

Background:

• Burkholderia pseudomallei and Burkholderia mallei are Gram-negative bacteria responsible for melioidosis and glanders.
• These pathogens are endemic globally and of increasing concern due to their potential as bioterrorism agents and opportunistic infections in immunocompromised individuals.
• Severe infections lead to high mortality rates, and both species exhibit significant antibiotic recalcitrance, with no existing vaccines.

Purpose of the Study:

• To review and compile existing literature on antimicrobial drug discovery for melioidosis and glanders.
• To highlight novel therapeutic approaches for combating diseases caused by B. pseudomallei and B. mallei.
• To leverage advancements in genome sequencing for identifying new therapeutic targets.

Main Methods:

• Literature review and compilation of studies on antimicrobial drug discovery.
• Focus on novel therapeutic strategies and target identification.
• Analysis of research facilitated by B. pseudomallei and B. mallei genome sequences.

Main Results:

• Identification of numerous studies focusing on antimicrobial drug discovery for melioidosis and glanders.
• Exploration of various novel therapeutic approaches against these challenging pathogens.
• Genome sequencing data has significantly aided in identifying potential drug targets.

Conclusions:

• There is a critical need for new antimicrobial agents and vaccines against B. pseudomallei and B. mallei.
• Ongoing research, aided by genomic information, is crucial for developing effective treatments.
• Novel therapeutic strategies are essential to combat the public health threat posed by these bacteria.